— McKesson Corporation (NYSE: MCK) reported third-quarter 2019 earnings of $3.60 per share, in line with the street projection. — Total revenue grew 9% to $57.62 billion, vs $55.07 billion expected. The topline was driven by its US Pharmaceutical and Specialty Solutions segment. — Revenues from US Pharma segment were $46.0 billion, up 10%, driven […]
“— McKesson Corporation (NYSE: MCK) reported third-quarter 2019 earnings of $3.60 per share, in line with the street projection. — Total revenue grew 9% to $57.62 billion, vs $55.07 billion expected. The topline was driven by its US Pharmaceutical and Specialty Solutions segment. — Revenues from US Pharma segment were $46.0 billion, up 10%, driven […]
· October 30, 2019
— McKesson Corporation (NYSE: MCK) reported third-quarter 2019 earnings of $3.60 per share, in line with the street projection.
— Total revenue grew 9% to $57.62 billion, vs $55.07 billion expected. The topline was driven by its US Pharmaceutical and Specialty Solutions segment.
— Revenues from US Pharma segment were $46.0 billion, up 10%, driven by branded pharmaceutical price increases and increased specialty pharmaceutical volumes.
— Reaffirms fiscal 2020 adjusted EPS guidance range of $14.00 – $14.60.
— CME shares have gained 0.7% immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
